Please assess the completion status of the following clinical trial:

Trial Title: Trial Comparing Three Strategies of Vaccination Against the Virus of Hepatitis B in HIV Infected Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Age Eligible for Study: 18 years - NA, Genders Eligible for Study: Both~Criteria~Inclusion criteria:~* HIV infection~* T CD4 count cell level above 200 per mm3~* Serology Hepatitis B negative (AgHBs, AbHBs and AbHBc negative)~* unchanged ARV for the last 3 months for patients who are receiving ARV at the screening visit~* Undetectable for the last 6 months with ARV for any patient with T CD4 level below 350 per mm3~* Pregnancy test negative at the screening and inclusion visits~Exclusion Criteria:~* Any injection of the vaccine against Hepatitis B in the medical history~* Acute cytolysis in the last 3 months with transaminases equal or above 5 times the upper normal range for HIV-HCV coinfected patients, or transaminases equal or above 2 times the upper normal for non coinfected patients~* Any vaccine received one month before the inclusion~* History of intolerance to any component of GenHevac-B~* Evolutive opportunistic infection treated the month before the screening visit~* Severe and acute pyretic infection or unexplained fever the week before inclusion~* Evolutive hemopathy or solid-organ cancer~* Prothrombin factor equal or below 50 percent and/or platelets equal or below 50 000 per mm3~* Immunosuppressive treatment or general corticotherapy (equal or above 0,5 mg per kg per day during above 7 days) in the last 6 months before the screening visit~* Previous Immunomodulating treatment (interferon, interleukin-2,etc) or plan in the next 6 months~* Splenectomy~* Decompensated cirrhosis (Child Pugh B or C)~* Kidney deficient function (creatinine clearance below 50 ml per mn)~* Other immunocompromised condition not related to HIV infection (solid-organ transplantation, chemotherapy in the last 6 months)~* Any participation to another clinical trial plan until Week 28

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): GenHevac-B 20 microgramme Intramuscular use at M0, M1, M6
- B (Type: EXPERIMENTAL): GenHevac-B 40 microgramme Intramuscular use at M0, M1, M2, M6
- C (Type: EXPERIMENTAL): GenHevac-B 4 microgramme Intradermal use at M0, M1, M2, M6

Based on this trial design, predict the completion outcome and termination type (if applicable).